Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient

A technology for active ingredients and inflammatory diseases, which can be used in medical preparations containing active ingredients, drug combinations, and resistance to vector-borne diseases, etc., and can solve problems such as unclear mechanism of action of degranulation inhibitors.

Active Publication Date: 2017-11-28
CHUNG ANG UNIV IND ACADEMIC COOP FOUND
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among these drugs, the drug action points of chemotransmitter action inhibitors and chemotransmitter synthesis inhibitors are relatively clear, but the mechanism of action of degranulation inhibitors is not clear, and, if given for a long time, these drugs will cause various side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient
  • Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient
  • Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0128] Culture of Lactococcus chungangensis

[0129] Lactococcus chungangensis is a strain isolated from activated sludge bubbles in our laboratory. This strain was deposited at the Korean Type Culture Collection (KCTC). Lactococcus chungangensis was inoculated into tryptic soy broth (TSB: Tryptic Soy Broth), and cultured at 30° C. for 24 hours in a shaking incubator. Each cell density was measured using a fully automatic quantitative drawing microplate reader (model Infinite F200, Tecan, Mannedorf, Switzerland).

Embodiment 2

[0131] Evaluation of the effect of Lactococcus chungangensis on macrophages and keratinocytes

[0132] Toxicity evaluation of Lactococcus chungangensis on RAW264.7 cells and HaCaT cells

[0133] The cytotoxicity of Lactococcus chungangensis cultured in Example 1 above was measured. The mouse macrophage cell line RAW264.7 cells and human keratinocyte cell line HaCaT cells were used in the cytotoxicity assay, and the cell viability test was carried out to measure the cytotoxicity. RAW264.7 cells and HaCaT cells were subcultured 4-5 times in 1 week, and the culture medium was DMEM medium (Dulbecco's Modified Eagle's Medium) containing 20 / ml gentamycin solution and 10% fetal bovine serum (FBS). 37°C, 5% CO 2 cultivated in an environment. To measure cell viability, 1 × 10 5 The concentration of cells / well was used to culture RAW264.7 cells and HaCaT cells for 24 hours. Add Lactococcuschungangensis to 10 9 The concentration of cells / ml was cultured in fresh DMEM medium with...

Embodiment 3

[0139] In Vitro Evaluation of Antiallergic Efficacy of Lactococcus chungangensis

[0140] Comparison of β-hexosaminidase secretion from mast cells (HMC-1) induced by Lactococcus chungangensis

[0141] The secretion of β-hexosaminidase is widely used as a major factor indicating the activation and degranulation of mast cells. Therefore, in this study, the human mast cell line HMC-1 cells were used to measure the secretion of β-hexosaminidase. HMC-1 cells were subcultured 4-5 times in 1 week, and the medium was IMDM (Iscove'smodified Dulbecco's Medium) medium containing 20 μg / ml gentamycin solution and 10% fetal bovine serum, and cultured at 37°C, 5%CO 2 cultivated in an environment. The cells were divided into 1×10 6 The concentration of cells / well was cultured in 24-well plates, and Lactococcus chungangensis was cultured at 1×10 9 The concentration of cells / ml was added to Tyrode's buffer (137mM NaCl, 2.7mM KCl, 1.8mM CaCl 2 , 1.1mM MgCl 2 , 11.9mM NaHCO 3 , 0.4mM N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The composition, of the present invention, containing Lactococcus chungangensis as an active ingredient, has excellent effects of preventing or treating inflammatory diseases, inhibiting the secretion of nitric oxide and prostaglandin E2, which are major inflammatory factors, and inhibiting the secretion of beta-hexosaminidase and histamine, which are major factors related to allergies, and also significantly inhibits the production of skin disease-related cytokines and chemokines. The effects are on the same level as those of conventional therapeutic agents, even compared therewith, for skin diseases (tacrolimus), and thus the composition can be used as a preventive or therapeutic agent for inflammatory diseases. In addition, the composition according to the present invention exhibits an antibacterial activity against Staphylococcus aureus, which is a microorganism inducing secondary infection and the like of atopic dermatitis, and thus can be used in preventing or treating bacterial infection.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases containing Lactococcus chungangensis as an active ingredient. Specifically, the composition of the present invention inhibits macrophages from releasing nitric oxide and inflammatory cytokines, and inhibits mast cells from expressing histamine or allergy-inducing cytokines, so it can be used for treating inflammatory diseases or allergic diseases. In addition, the composition of the present invention exhibits antibacterial activity against Staphylococcus aureus, microorganisms causing secondary infections of atopic dermatitis, etc., and thus is useful for treating bacterial infections. Background technique [0002] This application claims priority from Korean Patent Application No. 10-2015-0043602 filed on Mar. 27, 2015, the entire contents of which are incorporated herein by reference. [0003] Traditionally, inflammation is the expression o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/744A61P29/00A61P31/04A61Q17/00A61Q19/00A23L33/135
CPCA23L33/135A61K8/99A61K35/744A61Q17/005A61Q19/00A61K2800/10A23V2400/21A61Q19/007C12N1/20A61P29/00A61P31/04Y02A50/30C12R2001/46C12N1/205A61K35/74
Inventor 金原用崔禹镇
Owner CHUNG ANG UNIV IND ACADEMIC COOP FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com